Bisacodyl Suppository
NDC Package 83720-550-25

11-digit billing NDC: 83720055025

Package Information

Bisacodyl (bisacodyl suppositories) suppositories is - tear off one suppository from the strip- peel apart the wrapper- continue peeling apart to almost the full length of the suppository- gently remove the suppository from the wrapper- lie on your side and push suppository, with pointed end first, high into the rectum so it will not slip out- retain it for 15 to 20 minutes- Do not exceed recommended dose- if suppository seems soft, place in refrigerator for a short time before use. Adults and children 12 years and over 1 suppository once daily Children 6 to under 12 years 1/2 suppository once daily Children under 6 years    Ask a doctor. This formulation utilizes a suppository delivery system. Marketed by Oncor Pharmaceuticals, this product is identified by NDC 83720-550 and is authorized under FDA application M007.

Identification & Billing

NDC Package Code
83720-550-25
Package Description
12 SUPPOSITORY in 1 CARTON
Product Code
11-Digit Billing Format
83720055025
RxNorm Crosswalk
RxCUI: 198509 - bisacodyl 10 MG Rectal Suppository

Clinical Specifications

Proprietary Name
Bisacodyl
Non-Proprietary Name
Bisacodyl Suppositories
Substance Name
Bisacodyl
Dosage Form
Suppository - A solid body of various weights and shapes, adapted for introduction into the rectal orifice of the human body; they usually melt, soften, or dissolve at body temperature.
Administration Route
Rectal - Administration to the rectum.
Active Ingredient(s)
Usage Information
- tear off one suppository from the strip- peel apart the wrapper- continue peeling apart to almost the full length of the suppository- gently remove the suppository from the wrapper- lie on your side and push suppository, with pointed end first, high into the rectum so it will not slip out- retain it for 15 to 20 minutes- Do not exceed recommended dose- if suppository seems soft, place in refrigerator for a short time before use. Adults and children 12 years and over 1 suppository once daily Children 6 to under 12 years 1/2 suppository once daily Children under 6 years    Ask a doctor

Regulatory & Marketing

Labeler Name
Oncor Pharmaceuticals
Product Type
Human Otc Drug
FDA Application #
M007
Marketing Category
OTC MONOGRAPH DRUG -
Start Marketing Date
02-01-2025
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 83720-550-25 identifies a specific commercial package of 12 suppository in 1 carton of Bisacodyl, a human over the counter drug labeled by Oncor Pharmaceuticals. This suppository is formulated for rectal use and contains bisacodyl as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Oncor Pharmaceuticals on February 01, 2025. The current certification is valid through December 31, 2026.

How is this Oncor Pharmaceuticals product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 83720055025. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
83720-550-25
11-Digit CMS (5-4-2)
83720-0550-25

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.